Revolution Medicines Inc. recently provided an update on its clinical pipeline targeting RAS-addicted cancers, highlighting progress across multiple investigational drugs. The company reported that over 2,500 patients have been treated with its RAS$(ON)$ inhibitors and that eight randomized Phase 3 registrational trials are active or planned for 2026. Four clinical-stage investigational drugs—daraxonrasib, zoldonrasib, elironrasib, and RMC-5127—are being evaluated for pancreatic, non-small cell lung, and colorectal cancers. Daraxonrasib showed compelling monotherapy results in previously treated patients, as well as encouraging safety and efficacy in combination with pembrolizumab and chemotherapy. Zoldonrasib and elironrasib also demonstrated promising initial safety and antitumor activity in early trials. Registrational trials are ongoing or in advanced planning stages for each candidate, with enrollment completed in key studies for pancreatic cancer and ongoing trials for non-small cell lung cancer. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.
Comments